Patient characteristics associated with hypoglycaemia frequency during insulin glargine 100 U/ mL (Gla-100) titration and clinical outcomes at Week 24 were examined using participant-level data from 16 treat-to-target trials involving individuals with type 2 diabetes mellitus who were inadequately controlled with oral antidiabetes drugs and were initiating Gla-100 (n = 3549).
Patient characteristics associated with hypoglycaemia frequency during insulin glargine 100 U/ mL (Gla-100) titration and clinical outcomes at Week 24 were examined using participant-level data from 16 treat-to-target trials involving individuals with type 2 diabetes mellitus who were inadequately controlled with oral antidiabetes drugs and were initiating Gla-100 (n = 3549).
Hypoglycaemia (plasma glucose <3.9 mmol/L or severe) during the first 8 weeks of titration was stratified by number of events (0, 1-3 and ≥4), resulting in 72.5%, 20.6% and 6.9% of participants in each group, respectively. Changes in glycaemia, body weight and insulin dose from baseline to Weeks 12 and 24 were analysed. Hypoglycaemia was more common in participants with lower BMI and fasting C-peptide, and in those undergoing sulfonylurea treatment. Glycaemic outcomes at Week 24 were similar in each hypoglycaemia group, despite the fact that the Week 24 mean daily dose and dose increase for Gla-100 were highest in participants without hypoglycaemia and were lowest in those experiencing ≥4 events. The risk of hypoglycaemia during Gla-100 titration depends mainly on patient characteristics and on sulfonylurea use and may delay dose titration, which apparently has little effect on short-term glycaemic control in a clinical trial setting.
clinical trial, C-peptide, hypoglycaemia, insulin glargine, insulin initiation, type 2 diabetes mellitus 1 | INTRODUCTION Type 2 diabetes mellitus (T2DM) is usually treated with diet and lifestyle modification, followed by oral antidiabetes drugs (OADs), but many patients eventually require basal insulin to control blood glucose and reach glycaemic targets. 1 Early initiation of basal insulin is clinically more beneficial and is more cost-effective than a delay until failure of 3 OADs 2,3 and is recommended by international guidelines, especially for individuals with severe hyperglycaemia. (Tables S2 and S3 , Supporting Information).
| Clinical outcomes 3.2.1 | Discontinuation rates
Overall, 129 study participants (3.6%) discontinued treatment during the first 8 weeks and another 232 (6.5%) discontinued later in the course of the study. For each study period, the discontinuation rate was not found to be associated with the number of hypoglycaemia events during titration. 
| Efficacy outcomes by hypoglycaemia events

| Basal insulin titration
At similar baseline Gla-100 doses, dose increment over time differed when analysed by hypoglycaemia frequency (Figure 2A ). Gla-100 dose increments were lower and slower to rise, among participants experiencing hypoglycaemia vs those who did not. The mean daily Gla-100 dose at Week 24 was highest in those with no hypoglycaemia (Table S4 , Supporting Information).
| Severe and non-severe hypoglycaemia
During titration (Weeks 0-8) and throughout the continuing study period (Weeks 9-24), 0.9% and 1.2% of participants, respectively, reported a severe hypoglycaemia event. Participants who reported no non-severe hypoglycaemia event during titration also reported no severe hypoglycaemia event during this period; only 0.7% of this group reported a severe event and 19.5% reported a non-severe FIGURE 1 Mean HbA1c at baseline and Weeks 12 and 24 after Gla-100 initiation. Gla-100, insulin glargine 100 U/mL; HbA1c, glycated haemoglobin A1c event during Weeks 9 to 24 (Table S4 , Supporting Information). A higher incidence and higher event rate of severe hypoglycaemia were observed in participants with 1 to 3 or ≥4 non-severe hypoglycaemia events, both during titration and later in the course of the study. Similarly, event rates for non-severe hypoglycaemia were highest in participants with ≥4 non-severe hypoglycaemia events during titration, both during the first 8 weeks and later in the course of the study (Table S4 , Supporting Information).
| Body weight and BMI
Mean body weight and BMI at baseline differed considerably between hypoglycaemia groups (Table S1 , Supporting Information):
mean weight change from baseline to Week 24 was 1.8 (3.7) kg in those not experiencing hypoglycaemia events, 2.2 (3.5) kg in those experiencing 1 to 3 hypoglycaemia events and 1.9 (3.4) kg in those experiencing ≥4 hypoglycaemia events. Weight change in each group did not appear to be associated with the final Gla-100 dose, but was associated with concomitant OAD therapy (Table S4 , Supporting Information). Weight gain ranged from 0.7 kg with metformin and without hypoglycaemia events to 3.9 kg with sulfonylurea and with ≥4 hypoglycaemia events.
| DISCUSSION
Recognizing the heterogeneity of the T2DM population at insulin initiation, this post-hoc analysis was undertaken to identify patient characteristics that might influence the response to basal insulin in terms of hypoglycaemia risk during titration. The incidence of hypoglycaemia in this population of insulin-naive individuals with T2DM
was within expected boundaries, with 27.5% of participants reporting hypoglycaemia events (non-severe or severe), only 6.9% of whom experienced ≥4 events during the 8-week titration period.
Higher risk of hypoglycaemia during titration was also associated with a continued higher risk of non-severe and severe events throughout the later study period, indicating the importance of avoiding or reducing hypoglycaemia early during titration to minimise long-term risk. Our analysis has identified patient characteristics that may predispose to an increased risk of hypoglycaemia during insulin titration. These are lower body weight and BMI at the time of insulin initiation and low levels of fasting C-peptide, characterising an insulin-sensitive group that may require a lower dose of basal insulin to reach glycaemic targets, and therefore a more tailored titration strategy and/or more vigilance regarding hypoglycaemia events. As glutamic-acid-decarboxylase antibodies were not measured in these studies, it is also possible that the lean, more C-peptide-deficient subgroup included a subpopulation with latent autoimmune diabetes in adults (LADA), subsumed within the heterogeneous T2DM population. 7 Our results add to the existing evidence Gla-100. This finding suggests that early occurrence of hypoglycaemia during titration does not necessarily prevent patients from achieving short-or longer-term glycaemic targets; however, these outcomes have been observed in a clinical research setting, where participants received a monitored forced insulin titration to achieve the predefined FPG target. As reported previously, 9 it is also uncertain whether early A, Change in Gla-100 dose over study duration and B, mean dose at baseline and Weeks 12 and 24, stratified by number of hypoglycaemia events occurring during forced Gla-100 titration (Weeks 0-8). Gla-100, insulin glargine 100 U/mL hypoglycaemia during Gla-100 titration and recurrent hypoglycaemia later in the course of the studies induce a negative effect on treatment satisfaction or quality-of-life as such data were not systematically measured. Our findings, however, showed that individuals with hypoglycaemia during titration continue to experience considerably more severe and non-severe hypoglycaemia events than those without hypoglycaemia during titration. In addition, it is unclear how these results transfer to real-world use, as in daily practice a forced insulin titration period is not standard practice and daily insulin doses are generally lower than those in clinical trials. Therefore, in real-world practice, early and recurrent hypoglycaemia after insulin initiation might have a significant negative impact on mid-and long-term glycaemic control as fear of (and experienced) hypoglycaemia events is often associated with insufficient insulin titration, reduced adherence and compliance to insulin treatment, and higher rates of discontinuation of insulin treatment than those observed in randomized controlled trials. [10] [11] [12] [13] 
